Sintilimab Plus Chemotherapy for EGFR-Mutated Non-Squamous NSCLC With Disease Progression After EGFR TKI Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Respiratory Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
Lancet Respir Med 2023 May 05;[EPub Ahead of Print], S Lu, L Wu, H Jian, Y Cheng, Q Wang, J Fang, Z Wang, Y Hu, L Han, M Sun, L Miao, C Ding, J Cui, K Wang, B Li, X Li, F Ye, A Liu, Y Pan, S Cang, H Zhou, X Sun, Y Shen, S Wang, W Zhang, Y HeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.